Free Access
J Extra Corpor Technol
Volume 37, Number 4, December 2005
Page(s) 364 - 368
Published online 15 December 2005
  1. Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 2004;30:315–27. [CrossRef] [PubMed] [Google Scholar]
  2. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685–9. [CrossRef] [Google Scholar]
  3. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952–9. [CrossRef] [Google Scholar]
  4. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE 1 trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. J Am Coll Cardiol. 2002;39:16A. [CrossRef] [Google Scholar]
  5. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–63. [CrossRef] [PubMed] [Google Scholar]
  6. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking angiomax to reduced clinical events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092–6. [CrossRef] [Google Scholar]
  7. Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96:383–6. [Google Scholar]
  8. Koster A, Spiess B, Chew D, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2004;93:356–9. [CrossRef] [Google Scholar]
  9. Jabr K, Johnson JH, McDonald MH, et al. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2004;36:174–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Baker T, Chan R, Hill F. Anticoagulant monitoring techniques in a heparin-induced thrombocytopenia patient undergoing cardiopulmonary bypass using bivalirudin anticoagulant. J Extra Corpor Technol. 2004;36:371–4. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  11. Clayton S, Acsell J, Crumbley AJ, Shackelford A, Uber WE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg. 2004;78:2167–9. [CrossRef] [Google Scholar]
  12. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004;77:925–31. [CrossRef] [Google Scholar]
  13. McDonald SB, Kattapurum BM, Saleem R, Joist HJ, Avidan M, Despotis GJ. Monitoring hirudin anticoagulation in two patients undergoing cardiac surgery with a plasma-modified ACT method. Anesthesiology. 2002;97:509–12. [CrossRef] [PubMed] [Google Scholar]
  14. Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm. 2003;60:1841–9. [CrossRef] [PubMed] [Google Scholar]
  15. Measday MA, Zucker MLF. Optimizing mangement of hirudin anticoagulation. J Extra Corpor Technol. 2005;37:66–70. [Google Scholar]
  16. Koster A, Yeter R, Buz S, et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: Results of a pilot study. J Thorac Cardiovasc Surg. 2005;129:1391–4. [CrossRef] [Google Scholar]
  17. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:920–5. [Google Scholar]
  18. Fabrizio MC. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001;33:117–25. [Google Scholar]
  19. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg. 2001;93:28–32. [CrossRef] [PubMed] [Google Scholar]
  20. Koster A, Despotis G, Gruendel M, et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2002;95:26–30. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.